DR8 DataRelease
Release Date: 04/01/2014
| SDY261: MicroRNA Regulation of Human Protease Genes | |||||||||||||
| Status: | New | ||||||||||||
| Description: | the human protease genes required for influenza virus replication were determined and validated using RNA interference approaches. The genes validated as critical for influenza virus replication were ADAMTS7, CPE, DPP3, MST1, and PRSS12, and pathway analysis showed these genes were in global host cell pathways governing inflammation (NF-kB), cAMP/calcium signaling (CRE/CREB), and apoptosis. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3KPHZF88E | ||||||||||||
| Subjects: | 1 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY262: SWHP03 A novel pig model of Helicobacter pylori infection demonstrating Th1 and cytotoxic T cell responses | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Pigs were divided into 4 groups of uninfected (n=9), infected with H. pylori strain J99 (n=9), strain SS1 (n=8) and SW-SS1 (n=9). Following a 12-hour fasting period, bacterial challenge was performed by orogastric gavage with 1x1010 CFU H. pylori live organisms (strains J99, SS1 or SW-SS1) resuspended in sterile brucella broth administered on days 0 and 2 of the study. As a control, the uninfected group received sterile brucella broth without any bacteria. A delay in gastric emptying was ensured by oral administration of brucella broth supplemented with fetal bovine serum (FBS) prior to the bacterial or mock challenges. To suppress gastric acidity and to increase the efficiency of H. pylori colonization, all pigs received Famotidine (1mg/kg) intramuscularly 90 minutes prior to each bacterial and control inoculation and 5% urea was added to drinking water for 4 days post-infection to provide sufficient substrate for H. pylori urease and to increase gastric pH. Pigs were monitored and scored for clinical signs of disease daily. Peripheral blood was collected from the vena cava weekly to study systemic immune responses by flow cytometry. Pigs were euthanized between day 51 and 60 post-infection to assess gastric colonization with H. pylori, to study lesions and local immune responses in the gastric mucosa and lymph node (GLN). Tissue was collected from 3 major regions of the stomach: fundus gland (F), pyloric gland (P), cardiac gland (C) and further subdivided in 2 sections (F-A, F-B, P-A, P-B, C-A, C-B) for specific applications. Furthermore, Spleen and GLN were collected for further analysis. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3BAR04LX3 | ||||||||||||
| Subjects: | 35 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY264: Strategies to alleviate original antigenic sin | |||||||
| Status: | New | ||||||
| Description: | They found that dendritic cell-activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalenebased oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3EQ20FG3W | ||||||
| Subjects: | 21 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY269: Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine) | |||||||||||||||
| Status: | New | ||||||||||||||
| Description: | Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season. | ||||||||||||||
| Program/Contract: |
|
||||||||||||||
| DOI: | 10.21430/M3CDX6TL4I | ||||||||||||||
| Subjects: | 63 | ||||||||||||||
| Study PI, contact: |
|
||||||||||||||
| Publications: |
|
||||||||||||||
| Resources: |
|
||||||||||||||
| Assays: |
|
||||||||||||||
| Clinical Assessments: | None | ||||||||||||||
| SDY270: Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine) | |||||||||
| Status: | New | ||||||||
| Description: | Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3H9N1SFLO | ||||||||
| Subjects: | 30 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY271: Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine (See companion studies SDY61 2007 / SDY269 2008 / SDY270 2009) | |||||||||
| Status: | New | ||||||||
| Description: | To demonstrate that the gene signatures identified in this study can generate new hypotheses, we selected one gene in the predictive signature, calcium/calmodulin-dependent protein kinase IV (CaMKIV), for functional validation experiments. The CamkIV gene is involved in several processes of the immune system, such as T cell development,inflammatory response and hematopoietic stem cell maintenance. However, nothing is known about the possible role of CaMKIV in B cell responses. The fold-change in expression of the CaMKIV gene on day 3 post-TIV vaccination is negatively correlated with the antibody response on day 28 post-vaccination in two independent trials. Additionally, fold-change expression of CaMKIV is negatively correlated with the expansion of IgG-secreting plasmablasts at day 7, suggesting a possible role for this gene in the regulation of antibody responses to influenza vaccination. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M321YJ41HJ | ||||||||
| Subjects: | 36 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY1: Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab (an anti-IgE Monoclonal Antibody) | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Allergic rhinitis affects 20 to 40 million Americans annually. Allergy symptoms, which can range from mild to seriously debilitating, may affect quality of life. Left untreated, allergic rhinitis can exacerbate or trigger more serious conditions, such as asthma and sinus inflammation. Individuals with allergies react to harmless particles such as dust or pollen. Proteins in the blood called IgE antibodies treat the harmless particles as invaders and trigger an immune system response. The immune response results in harmful inflammation of healthy tissues. In ragweed allergy, inflammation occurs in the airways and causes familiar allergy symptoms like sneezing, coughing, and general discomfort. Omalizumab is an investigational drug that has been shown to block the effects of IgE antibodies. The blocking effect of omalizumab is temporary, but giving the drug to people before their regular allergy shots may make the shots more effective. Participants in this study will be randomly assigned to receive injections of omalizumab or a placebo before an accelerated course of allergy shots (given over 12 weeks). The participants will return for follow-up for up to one year, and they may have as many as 27 study visits. |
||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M38Y09R3R9 | ||||||||||||
| Subjects: | 159 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: | |||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: |
|
||||||||||||
| SDY61: Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine) | |||||||||||
| Status: | Updated | ||||||||||
| Description: | Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3FH0SA2W0 | ||||||||||
| Subjects: | 12 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: | None | ||||||||||
| SDY167: VRC304 - A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP) Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | The primary objective was to evaluate the safety and tolerability of an investigational vaccine VRC-AVIDNA036-00-VP in humans at doses 1 mg and 4 mg administered intramuscularly using a needle-free injection system. The secondary objectives included evaluation of whether VRC-AVIDNA036-00-VP (at doses 1 mg and 4 mg) induced antibodies as assessed by an HAI assay at Day 0 and Week 12. Exploratory analyses included evaluation of the immunogenicity of VRC-AVIDNA036-00-VP at doses 1 mg and 4 mg using intracellular cytokine staining, ELISpot, neutralizing antibody assay, HAI assay to H1 or H3HA or other immunological assays at time intervals between Day 0 and Week 42. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3SGHW16WZ | ||||||||||||
| Subjects: | 45 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY180: Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine | |||||||||||||||||
| Status: | Updated | ||||||||||||||||
| Description: | Systems immunology approaches were employed to investigate innate and adaptive immune responses to influenza and pneumococcal vaccines. These two non-live vaccines show different magnitudes of transcriptional responses at different time points af- ter vaccination. Software solutions were developed to explore correlates of vaccine efficacy measured as antibody titers at day 28. These enabled a further dissection of transcriptional responses. Thus, the innate response, measured within hours in the peripheral blood, was dominated by an interferon transcriptional signature after influenza vaccination and by an inflammation signature after pneumo- coccal vaccination. Day 7 plasmablast responses induced by both vaccines was more pronounced after pneumococcal vaccination. Together, these results suggest that comparing global immune responses elicited by different vaccines will be critical to our understanding of the immune mechanisms underpinning successful vaccination. | ||||||||||||||||
| Program/Contract: |
|
||||||||||||||||
| DOI: | 10.21430/M3I44H8R17 | ||||||||||||||||
| Subjects: | 46 | ||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||
| Publications: |
|
||||||||||||||||
| Resources: |
|
||||||||||||||||
| Assays: |
|
||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||
| SDY212: Apoptosis and other immune biomarkers predict influenza vaccine (TIV 2008) responsiveness | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Despite the importance of the immune system in many diseases, there are currently no objective benchmarks of immunological health. In an effort to indentify benchmarks of immunological health, influenza vaccination was used in 30 young (20-30 years) and 59 older subjects (60 to 89 years) as models for strong and weak immune responses, respectively. Serological responses to influenza strains as well as a wide variety of other parameters, including gene expression, antibodies to hemagglutinin peptides, serum cytokines, cell subset phenotypes and in vitro cytokine stimulation were measured. Using machine learning, nine variables predicting antibody response with 84% accuracy were identified. Two of these variables are involved in apoptosis, which positively associated with the response to vaccination and was confirmed to be a contributor to vaccine responsiveness in mice. The identification of these biomarkers provides new insights into what immune features may be most important for immune health. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M37NGTHMDS | ||||||||||||
| Subjects: | 91 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY224: Immune Responses to Seasonal TIV 2010-2011 Influenza Vaccination in Humans (see companion study SDY396,SDY564) | |||||||||||||||
| Status: | Updated | ||||||||||||||
| Description: | High-frequency sampling combined with systems biology analysis of human peripheral blood cells following influenza vaccination was used to investigate T cell and B cell responses. Functional principal component analysis was used to examine time varying B cell vaccine response highlighting a single subject-specific mathematical pattern explaining ninety percent of the transcriptome variation. In addtition, daily sampling and monitoring of the proliferation marker Ki-67, revealed influenza-specific CD4 T cells do respond to vaccination. | ||||||||||||||
| Program/Contract: |
|
||||||||||||||
| DOI: | 10.21430/M37KMO7JLW | ||||||||||||||
| Subjects: | 14 | ||||||||||||||
| Study PI, contact: |
|
||||||||||||||
| Publications: |
|
||||||||||||||
| Resources: |
|
||||||||||||||
| Assays: |
|
||||||||||||||
| Clinical Assessments: | None | ||||||||||||||
| SDY241: Simulation and Prediction of the Adaptive Immune Response and Quantification of Early and Adaptive Immune Response Kinetics to Influenza A Virus Infection | ||||||||||
| Status: | Updated | |||||||||
| Description: | Seasonal and pandemic influenza A virus (IAV) continues to be a public health threat. Modeling approaches were used combined with experimental data to investigate innate and adaptive immune responses to IAV infection. Mathematical models developed describe the dynamic interactions between influenza virus, target cells, cytotoxic lymphocytes, and virus-specific IgG and IgM. A two-compartment model developed quantifies the effects of viral replication and adaptive immunity. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3ERWHDJEO | |||||||||
| Subjects: | 494 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||